STAAR Surgical Stock Falls After Largest Shareholder Broadwood Gains Board Influence

Core Viewpoint - STAAR Surgical Company is experiencing significant changes in its board of directors, which has led to a decline in its share price [1][2]. Group 1: Board Changes - Broadwood Partners has joined STAAR Surgical's Board of Directors, bringing Neal Bradsher, Richard LeBuhn, and Christopher Wang on board [2]. - The restructuring includes the departure of Chair Elizabeth Yeu and CEO Stephen Farrell, who will remain until January 31, 2026 [2]. - The board aims to enhance profitability and long-term value creation, as stated by director Louis Silverman [2]. Group 2: Shareholder Dynamics - Broadwood Partners, which owns 31% of STAAR's common stock, is committed to helping the company realize its full potential, focusing on its leading technology and strong financial position [3][4]. - STAAR Surgical previously failed to secure the necessary stockholder votes for a merger with Alcon Inc., leading to the termination of the deal [3]. Group 3: Stock Performance - STAAR shares are currently trading 10% below the 20-day simple moving average (SMA) and 19% below the 100-day SMA, indicating a bearish trend [5]. - The stock has decreased by 3.50% over the past 12 months and is closer to its 52-week lows than highs [5]. - The Relative Strength Index (RSI) is at 39.17, suggesting neutral territory, while the MACD is below its signal line, indicating bearish pressure [5][6]. Group 4: Analyst Ratings and Market Sentiment - Analysts have a consensus Hold rating for STAAR Surgical, with an average price target of $31.42 as investors await the earnings release [7]. - The Benzinga Edge scorecard indicates a moderate momentum score of 63.67/100, suggesting potential for recovery despite current pressures [8]. - Key resistance for the stock is identified at $24.50, with key support at $20.00 [9]. Group 5: Current Price Action - As of the latest publication, STAAR Surgical shares were down 4.61% at $20.82 [10].